
US President Donald Trump’s recent warning of a 25% tariff on countries trading with Iran introduces fresh uncertainty for India’s economic engagement with the West Asian nation, reports The Pharma Letter’s India correspondent.
The move, framed as part of Washington’s pressure campaign on Tehran, comes at a time when India’s exports to Iran, particularly in pharmaceuticals, have reached record highs.
Pharmaceutical exports surged 70% in 2025, reaching $44.26 million, the highest in five years, according to data from the Department of Commerce.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze